Navigation Links
EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198

Significant Survival Advantage Shown in Lung Cancer Model

ROCKVILLE, Md., Oct. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of interim Phase 1 pharmacokinetic results for its antimitotic agent, ENMD-1198, together with preclinical antitumor activity results. The data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held this week in San Francisco, California.

(Logo: )

Pharmacokinetic results demonstrate that once a day orally-administered ENMD-1198 has good pharmacokinetic (PK) parameters in cancer patients participating in a Phase 1 clinical study. In the first four cohorts of the dose-escalation trial in advanced cancer patients, ENMD-1198 demonstrated dose proportional PK exposures across the range of 5-30 mg/m2. ENMD-1198, a new chemical entity (NCE) based on a modified chemical structure of 2- methoxyestradiol (2ME2), was designed to decrease metabolism while retaining 2ME2's multiple mechanisms of action, including inducing apoptosis, disrupting microtubules, and inhibiting HIF-1alpha.

ENMD-1198 was evaluated in a preclinical model of non-small cell lung cancer (NSCLC) and demonstrated a three-fold increase in survival compared to Cisplatin, an approved agent for the treatment of this disease. Approximately 80% of the ENMD-1198 treated models remained on study until tumor dissemination evaluation. In prior preclinical studies, ENMD-1198 has been shown to be an orally active, antimitotic agent that leads to arrest of cell division and apoptosis in tumor cells. ENMD-1198 also exerts antiangiogenic activity that further contributes to its overall antitumor effects.

Mark R. Bray, Ph.D., EntreMed Vice President, Research, commented on the results, "Preclinical studies with ENMD-1198 continue to highlight its significant antitumor activity. These data demonstrate that ENMD-1198 achieves predictable plasma drug levels after once daily oral dosing in humans, consistent with prior preclinical results."

Dr. Bray commented further, "The ENMD-1198 Phase 1 study continues in refractory solid tumor patients with a current dose level that is approaching the maximum tolerated dose in preclinical models without any ENMD-1198-related toxicity. Preclinical studies are continuing to help define Phase 2 indications and assess potential toxicities when used in combination with approved agents. These data further support ENMD-1198's potential for broad application in treating patients with cancer."

To view the poster presentation, visit the Company's web site at

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. Panzem(R) is also in preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).


Ginny Dunn

Associate Director, Corporate Communications & Investor Relations

EntreMed, Inc.


SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
7. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
8. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
9. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
Post Your Comments:
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
Breaking Medicine News(10 mins):